Leaflet DAPLAX 200mg powder infusion solution


Indicated for: cancer

Route of administration: infusion

Substance: gemcitabine (antimetabolite antineoplastic)

ATC: L01BC05 (Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Gemcitabine is a chemotherapy medication used to treat various types of cancer, including lung, pancreatic, breast, and bladder cancer. It is an antimetabolite that interferes with DNA synthesis in cancer cells.

This medication is administered intravenously, usually in cycles, according to a schedule set by the doctor. Gemcitabine helps slow the growth and spread of cancer cells.

Common side effects include nausea, vomiting, fatigue, low blood cell counts, and hair loss. In rare cases, severe reactions such as liver or lung function impairment may occur.

It is essential to follow your doctor's instructions and undergo regular tests to monitor the treatment's effects and manage potential side effects.

General data about DAPLAX 200mg

  • Substance: gemcitabine
  • Date of last drug list: 01-03-2022
  • Commercial code: W56149001
  • Concentration: 200mg
  • Pharmaceutical form: powder infusion solution
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: DR. REDDY'S LABORATORIES (UK) LTD. - MAREA BRITANIE
  • Holder: DR. REDDY'S LABORATORIES ROMANIA S.R.L. - ROMANIA
  • Number: 7873/2015/01
  • Shelf life: 3 years

Pharmaceutical forms available for gemcitabine

Concentrations available for gemcitabine

  • 1000mg
  • 100mg/ml
  • 10mg/ml
  • 1g
  • 2000mg
  • 200mg
  • 38mg/ml
  • 40mg/ml